Research
Hormonal
Time-restricted eating (TRE), specifically early TRE, can improve cardiometabolic markers such as blood pressure and glucose control even in the absence of weight loss (eucaloric conditions).
If you have prediabetes, try eating within an early window (e.g., 8 am to 4 pm) without changing your total calories. You might see improvements in blood pressure and blood sugar control even if your weight stays the same.
ModerateSupportsMEDIUM confidence
one study conducted in our lab found that eucaloric (i.e., energy intake equals energy needs, and thus in absence of weight loss) early TRE impressively improved blood pressure while still improving oxidative stress, insulin sensitivity, and β cell responsiveness in men with prediabetes
Why this rating
Based on a single study from the authors' lab mentioned in a review; requires confirmation by larger studies.
Source
Effects of Intermittent Fasting on Cardiometabolic Health: An Energy Metabolism Perspective
Manuel Dote‐Montero et al. · Nutrients · 2022
DOI 10.3390/nu14030489
narrative_reviewCited 54×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Intermittent fasting (IF) regimens improve body composition and cardiometabolic risk factors compared to unrestricted eating, primarily through energy deficit, but do not provide additional benefits over continuous daily caloric restriction when energy balance is matched.Good
- Fasting induces a metabolic switch from glycogenolysis to gluconeogenesis, lipolysis, and ketogenesis, which is considered a main driver of the metabolic health benefits provided by IF.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →